{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:05:48Z","timestamp":1792602348359,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vascn.2024.107525","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:27:32Z","timestamp":1717720052000},"page":"107525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterization of ascending dose canine telemetry model supports its use in E14\/S7B QT integrated risk assessments"],"prefix":"10.1016","volume":"128","author":[{"given":"Alysia A.","family":"Chaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude W.","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Moye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lai","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangbiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree L.","family":"Steve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vascn.2024.107525_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2125.2000.00243.x","article-title":"The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing","volume":"50","author":"Allen","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2024.107525_bb0010","series-title":"E14 and S7B clinical and nonclinical evaluation of QT \/ QTc interval prolongation and Proarrhythmic potential \u2014 Questions and answers guidance for industry E14 and S7B clinical and nonclinical evaluation of QT \/ QTc interval prolongation and Proarrhythmic","author":"Anonymous","year":"2022"},{"key":"10.1016\/j.vascn.2024.107525_bb0015","series-title":"E14\/S7B Q&A training material","author":"Anonymous","year":"2022"},{"issue":"2","key":"10.1016\/j.vascn.2024.107525_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.vascn.2007.04.007","article-title":"A highly sensitive canine telemetry model for detection of QT interval prolongation: Studies with moxifloxacin, haloperidol and MK-499","volume":"56","author":"Chaves","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2024.107525_bb0025","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/cts.13103","article-title":"Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis","volume":"14","author":"Chui","year":"2021","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.vascn.2024.107525_bb0030","series-title":"Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase","volume":"Vol. 97(4)","author":"Darpo","year":"2015"},{"issue":"5","key":"10.1016\/j.vascn.2024.107525_bb0035","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acs.molpharmaceut.6b01118","article-title":"Analyzing the potential root causes of variability of pharmacokinetics in preclinical species","volume":"14","author":"Daublain","year":"2017","journal-title":"Molecular Pharmaceutics"},{"issue":"2","key":"10.1016\/j.vascn.2024.107525_bb0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bcp.13123","article-title":"Translating QT interval prolongation from conscious dogs to humans","volume":"83","author":"Dubois","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2024.107525_bb0045","first-page":"436","article-title":"Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis","volume":"2022","author":"Engwall","year":"2022","journal-title":"Clinical and Translational Science, September"},{"key":"10.1016\/j.vascn.2024.107525_bb0050","series-title":"Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs. In experimental animals (Vol. 51, issue 5, pp. 465\u2013475)","author":"Miyazaki","year":"2002"},{"key":"10.1016\/j.vascn.2024.107525_bib81","volume":"8 ed","author":"National Research Council","year":"2011","journal-title":"2011 National Research Council Guide for the Care and Use of Laboratory Animals"},{"issue":"1","key":"10.1016\/j.vascn.2024.107525_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vascn.2013.03.005","article-title":"A history of the role of the hERG channel in cardiac risk assessment","volume":"68","author":"Rampe","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107525_bb0060","author":"Rossman","year":"2023"},{"issue":"3","key":"10.1016\/j.vascn.2024.107525_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpt1979253358","article-title":"Simultaneous modeling of pharmacokinetics and pharmacodynamics: An improved algorithm","volume":"25","author":"Sheiner","year":"1979","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2024.107525_bb0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a Fully Integrated Nonclinical\u2013Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"March","key":"10.1016\/j.vascn.2024.107525_bb0075","article-title":"Journal of pharmacological and toxicological methods improving the in vivo QTc assay\u00a0: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute","volume":"121","author":"Vargas","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107525_bb0080","series-title":"Integration of modeling and simulation to support changes to ondansetron dosing. April","author":"Zuo","year":"2014"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:09:33Z","timestamp":1737756573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871924000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":17,"alternative-id":["S1056871924000352"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107525","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of ascending dose canine telemetry model supports its use in E14\/S7B QT integrated risk assessments","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107525"}}